Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4 th generation ...
Genezen reports that the company became the first CDMO to license CSL’s Cytegrity™ cell line production system that was designed for the production of lentiviral vectors (LVVs). “We have significant, ...
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Commencement of LENTICLAIR™ 1 ...
A new vector system known as lentiviral vectors can permanently integrate the gene into dividing and non-dividing cells. The capacity of lentiviral vectors to reliably integrate at various genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results